Increasing Point-of-Care Testing Workload Addressed with New Integrated Systems Solution
|
By LabMedica International staff writers Posted on 17 Mar 2015 |

Image: The new Ecosystem solution and approach helps tackle data management challenges faced by point-of-care coordinators in the clinical laboratory (Photo courtesy of Siemens Healthcare Diagnostics).

Image: The point-of-care (POC) testing Ecosystem solution and approach encompasses eight core components: device management, operator management, quality control, compliance reporting, competency management, inventory management, remote monitoring, and mobile access (Image courtesy of Siemens Healthcare Diagnostics).
Challenges faced by clinical laboratory point-of-care (POC) coordinators can now be more efficiently tackled with an innovative approach developed as a new component of an informatics solution for managing in vitro diagnostics (IVD) analyzers and operators.
Siemens Healthcare Diagnostics, of Siemens AG (Berlin and Munich, Germany), now offers its new Ecosystem solution, an integrated component of its RAPIDComm Data Management System, an informatics solution that centrally manages Siemens IVD analyzers and operators.
Ecosystem, which encompasses eight core components, includes device management, operator management, quality control, compliance reporting, competency management, inventory management, remote monitoring, and mobile access.
“Siemens Healthcare Diagnostics has been carefully analyzing the POC market and is ready to provide a holistic approach to testing,” said Afia Boamah, product manager of Blood Gas, Stratus CS & POC IT S at Siemens Healthcare Diagnostics, “POC testing continues to grow at a rapid pace and there is a strong need to provide fast and reliable results.” “Although solutions for each of the 8 core components do exist individually, efficiently managing all aspects of a POC testing program requires close collaboration among hospitals, device manufacturers, and IT vendors. The Siemens POC Ecosystem helps to address this challenge by implementing an integrated solution which improves the efficiency and effectiveness of POC programs,” added A. Boamah.
Ecosystem takes the core needs of a POC program into consideration with a focus on helping POC coordinators improve control, effectiveness, and transparency. It manages secure access to POC devices, oversees quality control, manages staff training, and identifies and resolves issues - from any location via the remote access facility. This helps ensure manageability of instruments and consumables for potentially hundreds of testing devices. External compliance requirements are also met, while reducing costs.
“We are working hand-in-hand with healthcare providers to adapt to clinical environments making use of handheld IT devices such as tablets and smart phones. The Ecosystem solution allows POC data management from anywhere within a hospital using these devices, which improves the ability of POC coordinators to quickly and efficiently resolve issues. This has been highlighted by customers as a critical requirement in a fast-paced laboratory environment,” said A. Boamah.
Related Links:
Siemens
Siemens Healthcare
Siemens Healthcare Diagnostics, of Siemens AG (Berlin and Munich, Germany), now offers its new Ecosystem solution, an integrated component of its RAPIDComm Data Management System, an informatics solution that centrally manages Siemens IVD analyzers and operators.
Ecosystem, which encompasses eight core components, includes device management, operator management, quality control, compliance reporting, competency management, inventory management, remote monitoring, and mobile access.
“Siemens Healthcare Diagnostics has been carefully analyzing the POC market and is ready to provide a holistic approach to testing,” said Afia Boamah, product manager of Blood Gas, Stratus CS & POC IT S at Siemens Healthcare Diagnostics, “POC testing continues to grow at a rapid pace and there is a strong need to provide fast and reliable results.” “Although solutions for each of the 8 core components do exist individually, efficiently managing all aspects of a POC testing program requires close collaboration among hospitals, device manufacturers, and IT vendors. The Siemens POC Ecosystem helps to address this challenge by implementing an integrated solution which improves the efficiency and effectiveness of POC programs,” added A. Boamah.
Ecosystem takes the core needs of a POC program into consideration with a focus on helping POC coordinators improve control, effectiveness, and transparency. It manages secure access to POC devices, oversees quality control, manages staff training, and identifies and resolves issues - from any location via the remote access facility. This helps ensure manageability of instruments and consumables for potentially hundreds of testing devices. External compliance requirements are also met, while reducing costs.
“We are working hand-in-hand with healthcare providers to adapt to clinical environments making use of handheld IT devices such as tablets and smart phones. The Ecosystem solution allows POC data management from anywhere within a hospital using these devices, which improves the ability of POC coordinators to quickly and efficiently resolve issues. This has been highlighted by customers as a critical requirement in a fast-paced laboratory environment,” said A. Boamah.
Related Links:
Siemens
Siemens Healthcare
Latest Technology News
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more




.jpg)



